Anavex Life Sciences Corp. (LON:0HFR)

Market Cap	263.53M -61.0%
Revenue (ttm)	n/a
Net Income	-29.68M
EPS	-0.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,872
Average Volume	10,145
Open	3.900
Previous Close	3.881
Day's Range	3.790 - 3.940
52-Week Range	2.730 - 13.988
Beta	1.07
RSI	35.94
Earnings Date	Feb 9, 2026

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2004
• Employees: 34
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HFR

Financial Performance

Financial numbers in USD